Published in FDA Law Weekly, May 26th, 2005
The test is U.S. Food & Drug Administration (FDA)-approved for the broad use of assessing the risk of preterm birth. It determines the presence of the fetal fibronectin protein in the birth canal. This adhesive protein works like a "glue," holding the maternal and fetal membranes together during pregnancy.
Fetal fibronectin is typically not present until the final 2 to 6 weeks of pregnancy. Women who are considered at high risk for preterm birth or who experience early signs and symptoms of labor - between 22 and 35...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of FDA Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.